HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and othe ...

HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock at a price to the public of $1.30 per share. The gross proceeds from the offering to Nexalin are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other offering ...

Core Viewpoint - Nexalin Technology, Inc. is initiating formal regulatory engagement with the FDA for its Gen-2 SYNC system, aimed at treating Alzheimer's disease, dementia, and mild cognitive impairment (MCI) [1][2]. Regulatory Engagement - The company plans to submit a Q-Submission ("Q-Sub") to the FDA to facilitate structured dialogue regarding clinical trial design [1][2]. - This decision follows recent publications, encouraging internal data, and preliminary feedback from the FDA, marking a critical step in advancing Gen-2 SYNC as a non-invasive therapeutic option [2]. Product Development - The Gen-2 SYNC system features technical enhancements over prior generations, including a redesigned enclosure and a proprietary 15 milliamp advanced waveform [3]. - The company is rebranding the device to clearly differentiate it from earlier versions, marketing it as "Gen-2 SYNC" [3]. Company Focus - Nexalin is committed to progressing regulatory engagement and advancing its neuromodulation platform as a promising therapeutic alternative for cognitive and neuropsychiatric disorders [3]. - The company designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology [5].

AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™HOUSTON, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion and launch of phases one through five of its proprietary virtual clinic and digital research ecosystem. The launch of Nexalin’s virtual clinic took plac ...

Core Viewpoint - Nexalin Technology, Inc. has received a patent for its Deep Intracranial Frequency Stimulation (DIFS™) technology, which aims to provide a non-invasive and drug-free treatment for substance use disorders, including opioid use disorder and alcohol use disorder [1][2][3] Company Overview - Nexalin Technology focuses on developing innovative neurostimulation products to address the global mental health crisis, utilizing bioelectronic medical technology to treat mental health issues [5] - The company's DIFS™ technology is designed to regulate neural pathways associated with addiction and withdrawal symptoms, potentially improving treatment outcomes for individuals with substance use disorders [1][2] Patent Significance - The patent granted by the USPTO for the "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder" enhances Nexalin's intellectual property portfolio and validates the innovative nature of its DIFS™ technology [1][3] - This patent is seen as a significant achievement for the company, reinforcing its position as a pioneer in non-invasive brain stimulation for addiction and mental health therapy [2][3] Market Context - Substance use disorders, including opioid dependency and alcoholism, represent a major public health challenge globally, with traditional treatment methods often facing issues of accessibility and side effects [2] - Nexalin's DIFS™ technology offers a forward-thinking alternative to conventional therapies, aiming to alleviate withdrawal symptoms and support long-term recovery without the risks associated with pharmaceutical treatments [2][3]

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. This significa ...

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin ...

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin ...

Product Development and Technology - Nexalin's Gen-1 device is classified as a Class II device by the FDA for treating anxiety and insomnia, but requires a new 510(k) application for marketing in the U.S. due to reclassification [19]. - The Gen-2 and Gen-3 devices utilize a new advanced waveform technology emitting at 15 milliamps, which is believed to penetrate deeper into the brain for enhanced patient response [22]. - Clinical trials for the Gen-3 device are planned to begin in Q1 2025 in the U.S., Brazil, and China, with preliminary safety data supporting the new technology [22]. - The Gen-2 device has been approved by the China National Medical Products Administration for treating insomnia and depression, allowing Wider to market it in China [41]. - The proprietary 15 milliamp waveform represents a more than 400% increase in power compared to the previous 4 milliamp devices, enhancing treatment efficacy without adverse side effects [28]. - The company has completed two prototypes of a Nexalin headset utilizing the new 15 milliamp waveform, with clinical testing already begun [52]. - The Gen-2 device will undergo approximately 18 to 24 months of clinical study before the PMA application for depression treatment is submitted [75]. - The company plans to launch over 1,000 Gen-2 and Gen-3 devices globally, aiming to disrupt the current mental healthcare model [83]. - The company is developing a home-based treatment solution for chronic insomnia to improve sleep hygiene [72]. - The company is developing a proprietary IT management platform for a virtual clinic model to integrate remote outpatient treatment, enhancing telehealth capabilities [101]. Financial Performance and Challenges - The company recognized $4,851 in equity method investment from the joint venture for the year ended December 31, 2024, compared to $0 in 2023 [37]. - The company incurred a comprehensive loss of $7,607,290 for the year ended December 31, 2024, compared to a loss of $4,685,427 for 2023, indicating a significant increase in losses year-over-year [130]. - The accumulated deficit as of December 31, 2024, was $84,645,231, up from $77,038,049 in 2023, reflecting ongoing financial challenges [130]. - The company plans to continue significant investments in research and development, which are expected to lead to increased operating losses in the coming years [131]. - Additional funding will be necessary to meet financial needs and pursue business objectives, with the company currently not cash flow positive [140]. - The company anticipates fluctuations in financial condition and operating results due to various uncontrollable factors, making it difficult to predict future performance [139]. Regulatory and Market Environment - The FDA has classified the Gen-2 device for treating insomnia and depression as a Class II medical device, allowing it to be marketed and sold in China [57]. - The company is currently analyzing its previous 510(k) application for anxiety and insomnia treatment in light of the FDA's December 2019 reclassification ruling [52]. - The NMPA requires local testing and clinical trials for Class II and Class III devices, which may affect the company's operations in China [55]. - The Joint Venture with Wider is subject to regulatory risks in China, which may impact the company's ability to monetize its operations there [54]. - The company may face regulatory risks related to its Joint Venture in China, which could affect its ability to raise capital and conduct business [210]. - The medical industry in China is highly regulated, and changes in regulations may affect the approval and commercialization of the company's products [179]. Intellectual Property and Competition - The company owns three existing patents and has four pending patents related to electro-stimulation techniques, with plans for additional patent filings [107]. - The company's success heavily relies on obtaining and maintaining patent protection in the United States and other countries [214]. - Patent application processes are expensive and time-consuming, potentially hindering the ability to protect intellectual property effectively [214]. - The company may not be aware of all third-party intellectual property rights that could impact current and future products [216]. - Competitors may develop alternative technologies that circumvent the company's patents, posing a risk to its competitive advantage [217]. - The company faces risks from third-party submissions and challenges to its patent rights, which could reduce their scope or invalidate them [216]. Operational and Strategic Initiatives - The company plans to develop a virtual clinic platform for remote diagnosis and treatment, allowing physicians to prescribe the Gen-3 headset in a private tele-psychiatry setting [31]. - A lead management system will connect mental health physicians with prospective patients, facilitating telehealth appointments and device shipments [102]. - The company is focused on building an intellectual property portfolio to maintain its competitive position in the market [111]. - The company is classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of certain reporting exemptions [123][127]. - The company currently employs 6 full-time employees and 1 part-time employee, supported by approximately 7 consultants [119]. Market Trends and Opportunities - The global chronic pain treatment market is projected to grow at a CAGR of 7% and generate revenue of $173 billion by 2033 [79]. - The global Alzheimer's therapeutics market is expected to reach $13.7 billion by 2030, up from $2.2 billion in 2020, reflecting a CAGR of 20% [82]. - The substance use disorder costs the United States over $740 billion annually in healthcare, crime, and lost productivity [76]. - The Centers for Medicare & Medicaid Services issued a reimbursement code for Cranial Electrotherapy Stimulators (CES) in January 2020, marking the first specific code for CES [88]. Risks and Uncertainties - The company relies on third parties for clinical trials and quality assurance, which introduces risks related to performance and compliance [154][155]. - The company may face significant delays in product development and commercialization due to reliance on collaborations and potential litigation [157]. - The company currently holds $1 million in product liability insurance coverage, which may not be adequate to cover all potential liabilities [168]. - The company anticipates increased competition in the neurostimulation field, which may impact its market position and product viability [163]. - Coverage and adequate reimbursement for the company's products may not be available, which could hinder profitable sales if approved [164]. - The company faces risks related to product liability lawsuits, which could lead to substantial liabilities and affect commercialization efforts [166].

Core Insights - Nexalin Technology, Inc. has received a Notice of Allowance from the USPTO for its patent on the DIFS™ technology aimed at treating substance use disorders [1][2][3] - The DIFS™ technology is a non-invasive, drug-free method designed to assist individuals with various substance use disorders, including opioid, alcohol, and stimulant addictions [1][2] - The newly allowed patent enhances Nexalin's intellectual property portfolio and positions the company as a leader in innovative medical technology [2][3] Company Overview - Nexalin Technology focuses on developing neurostimulation products to address the global mental health crisis, utilizing bioelectronic medical technology [5] - The company's DIFS™ technology aims to provide relief for mental health issues without adverse side effects, with existing products approved in multiple countries [5] Industry Context - Substance use disorders, including opioid addiction and alcoholism, are significant public health challenges affecting millions globally [2][3] - Traditional treatment methods, such as medication-assisted treatment and behavioral therapy, face issues related to accessibility and side effects, highlighting the need for alternative solutions like Nexalin's DIFS™ technology [2][3]